Pacific Edge (ASX:PEB) Tax Provision : A$0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pacific Edge Tax Provision?

Pacific Edge's tax provision for the six months ended in Sep. 2024 was A$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was A$0.00 Mil.

Pacific Edge Tax Provision Historical Data

The historical data trend for Pacific Edge's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Edge Tax Provision Chart

Pacific Edge Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Tax Provision

Get a 7-Day Free Trial

Pacific Edge Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Pacific Edge Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Pacific Edge Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (ASX:PEB) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

PFGTF:USA PEB:New Zealand

Address

87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016

Website

https://www.pacificedgedx.com

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.